NVCR vs VERO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVCR is a Sell and VERO is a Sell.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVCR’s FA Score shows that 1 FA rating(s) are green whileVERO’s FA Score has 1 green FA rating(s).
- NVCR’s FA Score: 1 green, 4 red.
- VERO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVCR’s TA Score shows that 2 TA indicator(s) are bullish while VERO’s TA Score has 3 bullish TA indicator(s).
- NVCR’s TA Score: 2 bullish, 9 bearish.
- VERO’s TA Score: 3 bullish, 5 bearish.
Price Growth
NVCR (@Medical Specialties) experienced а -7.63% price change this week, while VERO (@Medical Specialties) price change was -26.86% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.
Reported Earning Dates
NVCR is expected to report earnings on Feb 20, 2025.
VERO is expected to report earnings on Aug 14, 2023.
Industries' Descriptions
@Medical Specialties (-4.23% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| NVCR | VERO | NVCR / VERO | |
| Capitalization | 1.66B | 4.45M | 37,289% |
| EBITDA | -177.45M | -26.29M | 675% |
| Gain YTD | 7.904 | -74.153 | -11% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 509M | 82.5M | 617% |
| Total Cash | 911M | 4.93M | 18,494% |
| Total Debt | 596M | 83.9M | 710% |
NVCR | VERO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 95 | 100 | |
PRICE GROWTH RATING 1..100 | 61 | 95 | |
P/E GROWTH RATING 1..100 | 11 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VERO's Valuation (27) in the null industry is significantly better than the same rating for NVCR (100) in the Medical Specialties industry. This means that VERO’s stock grew significantly faster than NVCR’s over the last 12 months.
VERO's Profit vs Risk Rating (100) in the null industry is in the same range as NVCR (100) in the Medical Specialties industry. This means that VERO’s stock grew similarly to NVCR’s over the last 12 months.
NVCR's SMR Rating (95) in the Medical Specialties industry is in the same range as VERO (100) in the null industry. This means that NVCR’s stock grew similarly to VERO’s over the last 12 months.
NVCR's Price Growth Rating (61) in the Medical Specialties industry is somewhat better than the same rating for VERO (95) in the null industry. This means that NVCR’s stock grew somewhat faster than VERO’s over the last 12 months.
NVCR's P/E Growth Rating (11) in the Medical Specialties industry is significantly better than the same rating for VERO (100) in the null industry. This means that NVCR’s stock grew significantly faster than VERO’s over the last 12 months.
| NVCR | VERO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 88% | N/A |
| Stochastic ODDS (%) | 3 days ago 89% | 3 days ago 87% |
| Momentum ODDS (%) | 3 days ago 88% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 82% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 86% | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 84% | 3 days ago 90% |
| Advances ODDS (%) | 12 days ago 77% | 7 days ago 86% |
| Declines ODDS (%) | 3 days ago 90% | 5 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 81% | 3 days ago 90% |
| Aroon ODDS (%) | 5 days ago 88% | 3 days ago 89% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| HRIDX | 12.55 | -0.06 | -0.48% |
| Harbor Diversified Intl All Cp Admin | |||
| PRDMX | 49.87 | -0.52 | -1.03% |
| T. Rowe Price Diversified Mid Cap Gr | |||
| RCMPX | 16.34 | -0.19 | -1.15% |
| Lazard International Quality Gr R6 | |||
| JMGRX | 153.01 | -1.90 | -1.23% |
| Janus Henderson Enterprise I | |||
| LYFCX | 12.76 | -0.29 | -2.22% |
| AlphaCentric Life Sciences & Hlthcare C | |||
NVCR and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with MASS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then MASS could also see price increases.
| Ticker / NAME | Correlation To NVCR | 1D Price Change % | ||
|---|---|---|---|---|
| NVCR | 100% | -2.78% | ||
| MASS - NVCR | 45% Loosely correlated | +0.42% | ||
| VCYT - NVCR | 44% Loosely correlated | -2.97% | ||
| GH - NVCR | 44% Loosely correlated | -3.64% | ||
| KIDS - NVCR | 43% Loosely correlated | +1.06% | ||
| TWST - NVCR | 43% Loosely correlated | -5.31% | ||
More | ||||
VERO and
Correlation & Price change
A.I.dvisor indicates that over the last year, VERO has been loosely correlated with ANSLY. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if VERO jumps, then ANSLY could also see price increases.
| Ticker / NAME | Correlation To VERO | 1D Price Change % | ||
|---|---|---|---|---|
| VERO | 100% | -12.61% | ||
| ANSLY - VERO | 33% Loosely correlated | N/A | ||
| SSKN - VERO | 30% Poorly correlated | -2.90% | ||
| BRSYF - VERO | 30% Poorly correlated | N/A | ||
| NVCR - VERO | 27% Poorly correlated | -2.78% | ||
| INGN - VERO | 26% Poorly correlated | +1.01% | ||
More | ||||